Toggle Nav
Close
  • Menu
  • Setting

Matrine

Catalog No.
A3583
Alkaloid found in Sophora plant
Grouped product items
SizePriceStock Qty
10mM (in 1mL DMSO)
$99.00
In stock
100mg
$94.00
In stock
200mg
$165.00
In stock
500mg
$286.00
In stock
For scientific research use only and should not be used for diagnostic or medical purposes.

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

Background

Matrine (CAS 519-02-8) is an alkaloid derived from plants in the Sophora genus, with demonstrated anticancer and anti-inflammatory activities. It functions in part through agonism of kappa-opioid and possibly other receptors. Matrine inhibits the MNK45 gastric cancer cell line proliferation (IC50 = 540 μg/ml, MTT assay) by modifying protein expression profiles (e.g., NF-κB, XIAP, CIAP, p-ERK). In vitro, matrine induces apoptosis in NSCLC cells through ROS generation, caspase activation, and p38 pathway modulation. Animal studies suggest therapeutic roles in cardiac injury and sepsis-related lung inflammation.

Chemical Properties

Physical AppearanceA solid
StorageStore at -20°C
M.Wt248.36
Cas No.519-02-8
FormulaC15H24N2O
SynonymsSophocarpidine;Matridin-15-one;Vegard;α-Matrine
Solubility≥12.42 mg/mL in DMSO; ≥47.2 mg/mL in EtOH; ≥50.3 mg/mL in H2O with gentle warming and ultrasonic
Chemical Name(41S,7aS,13aR,13bR)-dodecahydro-1H-dipyrido[2,1-f:3',2',1'-ij][1,6]naphthyridin-10(41H)-one
SDFDownload SDF
Canonical SMILESO=C1N(C[C@@]2([H])[C@@]3([H])[C@]4([H])CCCN3CCC2)[C@]4([H])CCC1
Shipping ConditionSmall Molecules with Blue Ice, Modified Nucleotides with Dry Ice.
General tips We do not recommend long-term storage for the solution, please use it up soon.

Protocol

Cell experiment [1]:

Cell lines

MNK45 gastric cancer cell line

Preparation method

Soluble in water, ethanol, chloroform, toluene, and benzene. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.

Reacting condition

0.05, 0.10, 0.25, and 0.50 mg/ml for 48 h

Applications

Matrine showed a dose-dependent inhibition of the growth of MKN45 cells and the concentration needed for 50% inhibition of growth of MKN45 cells was 0.5 mg/ml. It was also found that after matrine treatment at 0.05, 0.1, 0.25, and 0.50 mg/ml, the IKKa, IjBa, IjBb, phospho-IjBa proteins levels in MKN45 cells were significantly higher than those in control cells. In addition, the p-ERK protein expression level in low dose matrine-treated MKN45 cells was significantly higher than that in high dose matrine-treated MKN45 cells.

Animal experiment [2]:

Animal models

Adult male BALB/c mice

Dosage form

25, 50 or 100 mg/kg, i.p.

Application

Treatment with matrine could significantly reduce LPS-induced mouse death, the accumulative mortalities during 3 days in high dose of matrine (100 mg/kg) treatment groups (55%) was significantly lower than that in LPS groups (80%). However, no protection was observed when mice received matrine treatment at dose of 25 mg/kg and 50 mg/kg. Matrine treatment could also significantly improve the lung injury, such as pulmonary edema, infiltration of inflammatory cells in the lung tissues and alveoli, and alveolar damage. There was no obvious change in lung structure in control and matrine groups.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1]. Luo C, et al. Inhibition of matrine against gastric cancer cell line MNK45 growth and its anti-tumor mechanism. Mol Biol Rep. 2012 May;39(5):5459-64.

[2]. Zhang B, et al. Antiinflammatory effects of matrine in LPS-induced acute lung injury in mice. Eur J Pharm Sci. 2011 Dec 18;44(5):573-9.

Quality Control